@Article{crph796,
AUTHOR = {Seki, Masafumi and Mitsutake, Kotaro and Shimizu, Atsuko and Honda, Daisuke and Ishigami, Ken and Yamanaka, Mitsuko and Kuwata, Yasuhiro and Ueda, Genji and Enami, Kazunori},
TITLE = {Ensitrelvir improved SARS-CoV-2 viral titers of COVID-19 patients refractory to remdesivir},
JOURNAL = {Current Research in Public Health},
VOLUME = {3},
YEAR = {2023},
NUMBER = {1},
PAGES = {27-31},
URL = {https://www.scipublications.com/journal/index.php/WJCMR/article/view/796},
ISSN = {2831-5162},
DOI = {10.31586/wjcmr.2023.796},
ABSTRACT = {Background: The titers of SARS-COV-2 antigens are frequently used as markers of viral activity and threshold for release from quarantine and treatment. COVID-19 patients were treated with several antiviral agents, including remdesivir (RDV) and ensitrelvir (ESV), which is a novel anti-SARS-CoV-2 agent recently suggested to have strong antiviral activity. Cases: We present the cases of two patients whose SARS-CoV-2 antigens were successfully decreased by oral administration of ESV after they could not be decreased by RDV drip infusion. Case 1 was a 74-year-old man who was admitted with SARS-CoV-2 infection and had been infected by the virus a month earlier and relapsed twice. He had been treated with rituximab for diffuse B cell lymphoma and not received vaccination for SARS-CoV-2. RDV was administered intravenously two weeks earlier and again 4 days earlier, but it failed to control the infection, and he was transferred to our hospital (day 1). Intravenous RDV was restarted on day 1, but viral antigens remained high until day 5. The RDV was then switched to oral ESV, and viral antigen titers were successfully decreased on days 8, 10, and 12. Case 2 was an 81-year-old man who was admitted with SARS-CoV-2 infection on day 0. He had heart failure and diabetes mellitus, and had not received vaccination for SARS-CoV-2. Intravenous RDV was started on day 1, but viral antigens were still high until day 8. He was then switched from RDV to oral ESV, and viral antigen titers were successfully decreased on day 11. Conclusions: These cases suggest that ESV might be more effective than RDV for reducing viral activity, and it is easy to administer orally.},
}

%0 Journal Article
%A Seki, Masafumi
%A Mitsutake, Kotaro
%A Shimizu, Atsuko
%A Honda, Daisuke
%A Ishigami, Ken
%A Yamanaka, Mitsuko
%A Kuwata, Yasuhiro
%A Ueda, Genji
%A Enami, Kazunori
%D 2023
%J Current Research in Public Health

%@ 2831-5162
%V 3
%N 1
%P 27-31

%T Ensitrelvir improved SARS-CoV-2 viral titers of COVID-19 patients refractory to remdesivir
%M doi:10.31586/wjcmr.2023.796
%U https://www.scipublications.com/journal/index.php/WJCMR/article/view/796

TY  - JOUR
AU  - Seki, Masafumi
AU  - Mitsutake, Kotaro
AU  - Shimizu, Atsuko
AU  - Honda, Daisuke
AU  - Ishigami, Ken
AU  - Yamanaka, Mitsuko
AU  - Kuwata, Yasuhiro
AU  - Ueda, Genji
AU  - Enami, Kazunori
TI  - Ensitrelvir improved SARS-CoV-2 viral titers of COVID-19 patients refractory to remdesivir
T2  - Current Research in Public Health
PY  - 2023
VL  - 3
IS  - 1
SN  - 2831-5162
SP  - 27
EP  - 31
UR  - https://www.scipublications.com/journal/index.php/WJCMR/article/view/796
AB  - Background: The titers of SARS-COV-2 antigens are frequently used as markers of viral activity and threshold for release from quarantine and treatment. COVID-19 patients were treated with several antiviral agents, including remdesivir (RDV) and ensitrelvir (ESV), which is a novel anti-SARS-CoV-2 agent recently suggested to have strong antiviral activity. Cases: We present the cases of two patients whose SARS-CoV-2 antigens were successfully decreased by oral administration of ESV after they could not be decreased by RDV drip infusion. Case 1 was a 74-year-old man who was admitted with SARS-CoV-2 infection and had been infected by the virus a month earlier and relapsed twice. He had been treated with rituximab for diffuse B cell lymphoma and not received vaccination for SARS-CoV-2. RDV was administered intravenously two weeks earlier and again 4 days earlier, but it failed to control the infection, and he was transferred to our hospital (day 1). Intravenous RDV was restarted on day 1, but viral antigens remained high until day 5. The RDV was then switched to oral ESV, and viral antigen titers were successfully decreased on days 8, 10, and 12. Case 2 was an 81-year-old man who was admitted with SARS-CoV-2 infection on day 0. He had heart failure and diabetes mellitus, and had not received vaccination for SARS-CoV-2. Intravenous RDV was started on day 1, but viral antigens were still high until day 8. He was then switched from RDV to oral ESV, and viral antigen titers were successfully decreased on day 11. Conclusions: These cases suggest that ESV might be more effective than RDV for reducing viral activity, and it is easy to administer orally.
DO  - Ensitrelvir improved SARS-CoV-2 viral titers of COVID-19 patients refractory to remdesivir
TI  - 10.31586/wjcmr.2023.796
ER  -